GRI Bio, Inc. announces positive flow cytometry data from the Phase 2a GRI-0621-IPF-02 clinical trial for Idiopathic Pulmonary Fibrosis (IPF).
The data confirms a disease-modifying mechanism and shows improvements in lung function and fibrosis resolution.
The Phase 2a study demonstrated a safety and tolerability profile different from existing treatment options.
Positive Flow Cytometry Data
Immune cell profiling confirms anti-fibrotic mechanism with increased IFN-gamma and reduced pro-fibrotic cytokines.
Dual Mechanism of Action
GRI-0621 acts as both an immunomodulator and an anti-fibrotic agent, showing favorable safety and tolerability.
Clinical Proof-of-Concept
Consistent data strengthens evidence of collagen turnover, lung tissue repair, and improved pulmonary function with GRI-0621.
- The Phase 2a study met primary and secondary endpoints, indicating potential disease modification and lung repair.
- Results suggest a promising treatment option for patients with Idiopathic Pulmonary Fibrosis, addressing an unmet medical need.
GRI Bio's Phase 2a study results reinforce the potential of GRI-0621 as a safe and effective treatment for IPF patients. The data supports further development and validation of this innovative therapy in the field of inflammatory and fibrotic diseases.